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the formation of thymidylate synthase ternary complex in human cancer
cells
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Summary We examined the importance of dosing interval between leucovonin (LCV) and 5-fluorouracil
(5-FU) on intracellular thymidylate synthase (TS) ternary complex. free TS and total TS protein levels in
human MCF-7 breast and NCI H630 colon cancer cell lines. A 2- to 3-fold increase in total TS was noted
when either cell line was exposed to 5-FU 1OMLm plus LCV (0.01 -10;jM) compared with a 1.4- to 1.6-fold
increase in total TS due to 5-FU 1O;IM alone. The amount of TS ternary complex formed was 2- to 3-fold
higher in both cell lines treated with the combination of 5-FU and LCV compared with 5-FU alone. TS
complex formation and total TS protein increased with LCV dose (O. 1 -1OIM). In MCF-7 cells, the maximal
increase in total TS protein and TS ternary complex formation was observed when 5-FU was delayed for 4 h
after the start of LCV exposure. In NCI H630 cells, maximal total TS protein and ternary complex formation
occurred when 5-FU was delayed for 18 h after the start of LCV exposure. The amount of free TS did not
change in either cell line whether 5-FU was given concurrently with LCV or delayed for up to 24 h. The
accumulation rate of intracellular folates in the form of higher glutamates Glu,-Glu, was rapid in MCF-7
cells (maximal formation after 4 h). whereas in H630 cells accumulation of higher polyglutamates continued to
increase up to 18 h. The time of peak folate polyglutamate (Glu,-Glu,) formation coincided with the time of
peak TS complex formation and total TS protein in each cell line. In these human carcinoma cell lines, the
LCV dose and interval between 5-FU and LCV play a role in increased TS total protein and TS ternary
complex: however, the amount of free TS is independent of the interval between 5-FU and LCV. The time-
and dose-dependent increases in TS ternary complex and TS total protein are associated with differences in the
accumulation of folate polyglutamates in these cell lines.
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The fluoropyrimidine 5-fluorouracil (5-FU) is the single most
active agent for the treatment of patients with colorectal
cancer and remains one of the most active chemotherapeutic
agents used in the treatment of patients with head and neck
as well as breast cancer (Moertel, 1978; Grem 1988. 1990).
One of the principal mechanisms of action of 5-FU is inhibi-
tion of the enzyme thymidylate synthase (TS). TS catalyses
the methylation of deoxyuridine monophosphate (dUMP) to
deoxythymidine monophosphate (dTMP) and is critical in de
novo pyrimidine nucleotide formation, essential for DNA
synthesis (Santi et al.. 1974; Danenberg, 1977). Fluorodeoxy-
uridine monophosphate (FdUMP), an active intracellular
metabolite of 5-FU, forms a covalent complex with TS in the
presence of the folate co-factor 5,10-methylene tetrahydro-
folate (5,1O-methylene-H4PteGlu), resulting in intracellular
thymidine depletion. Preclinical laboratory studies suggest
that the formation of TS ternary complex (TS-FdUMP-5.10-
methylene-H4PteGlu) is a critical step for the cytotoxicity of
the fluoropyrimidines (Santi et al.. 1974; Heidelberger. 1975;
Danenberg, 1977; Hardy et al., 1987). The stability and
amount of ternary complex formed has been shown to be
dependent on the concentration of the reduced folate sub-
strate 5,10-methylene-HJtteGlu (Lockshin and Danenberg,
1979). Leucovorin (LCV; folinic acid, 5-formyltetrahydro-
folate) is a reduced folate that, when metabolised intra-
cellularly, increases the intracellular reduced folate pool,
including 5,10-methylene-H4PteGlu. This increase in the
reduced folate pool results in enhanced formation and
stability of TS ternary complex (Houghton et al.. 1981; Mini
et al., 1987).
Several in vitro studies have demonstrated that co-admin-
istration of LCV enhances 5-FU cytotoxicity (Ullman et al..
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1978; Keyomarsi and Moran. 1986: Mini et al.. 1987: Petrelli
et al., 1987; Park et al.. 1988; Moran and Scanlon, 1991).
These studies suggest that concentrations of LCV in the
1.0-10JM range are optimal for potentiating the activity of
5-FU in human and non-human cancer cell lines. Intracellu-
lar reduced folate pools have been shown to increase with
increasing LCV dose; however. LCV concentrations above
1 gM may not further increase 5-FU cytotoxicity (Keyomarsi
and Moran, 1986). The duration of LCV exposure also
appears to be an important variable in the interaction of
LCV with 5-FU since folate polyglutamation is a time-depen-
dent process and the polyglutamates of 5.10-methylene-
H4PteGlu are 50- to 100-fold more potent in ternary complex
formation than the monoglutamate forms (Moran and Scan-
lon, 1991).
The concept of enhancing the activity of 5-FU by the
addition of folate in the form of LCV has been applied to the
treatment of patients with a variety of malignancies, includ-
ing advanced colorectal and breast cancers. Clinical studies
have demonstrated that response rates in patients with
advanced colorectal cancer have doubled with the addition of
LCV to 5-FU (Machover et al.. 1986; Erlichman et al.. 1988:
Petrelli et al., 1989; Poon et al.. 1989; Valone et al., 1989:
Advanced Colorectal Cancer Meta-Analysis Project. 1992).
In several randomised trials, the overall response to combina-
tion therapy with 5-FU LCV was superior to 5-FU alone for
the treatment of patients with advanced colorectal cancer.
and in one of these tnrals a small but significant increase in
survival was demonstrated (Poon et al.. 1989). More recently.
it has been shown that treatment with 5-FU plus LCV
prolongs disease-free survival and overall survival in patients
with Dukes' B and C colorectal cancer (Wolmark et al..
1993). All of these clinical studies have used a vanrety of
doses and schedules of LCV; however, the optimal dose and
schedule of LCV as a modulator of 5-FU have not been
clearly defined.
We have recently descnrbed an immunological assay using
TS monoclonal antibodies that can detect and quantitate the
amount of TS enzyme that is bound as ternary complex inDose and inteval of 54fluouracil and kucovorin
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human tumour cells following treatment with 5-FU or 5-FU
LCV (Johnston et al.. 1991; Drake et al.. 1993). We have
applied this assay to detect and quantitate the intracellular
amount of ternary complex within cells following treatment
with various doses and schedules of LCV. The goal of the
present study was to determine the importance of the dose
and interval of exposure between LCV and 5-FU on intracel-
lular TS ternary complex formation and TS protein levels in
human colon and breast cancer cell lines.
Materials and methods
Cell culture
The characteristics of the human colon cancer cell line NCI
H630 and the human breast cancer cell line MCF-7 have
been described previously (Soule et al.. 1973; Park et al..
1987). Cells were maintained in folate-free minimum essential
media (Gibco. Grand Island. NY. USA) supplemented with
50 nM L-leucovorin (Lederle), 10% dialysed fetal calf serum
(Gibco) and 2 mm glutamine (Gibco) and grown in 75 cm2
plastic culture flasks (Falcon Labware. Oxnard. CA, USA) at
3TC in a humidified 5% carbon dioxide incubator.
Growth inhibition studies
Equal numbers of MCF-7 and NCI H630 cells (2 x 10'ml)
were plated onto 25 cm' flasks (Falcon Labware). After 48 h.
cells were treated with either 5-FU or 5-FU plus LCV using
the schedule and doses of LCV described in Figure 1. Cells
were harvested 96 h after plating and an aliquot from each
flask was counted using a Coulter electronic cell counter
(Coulter Electronics. Hialeah. FL. USA).
5-FLE LC treatment schedule
Equal numbers of cells (1 x 10' ml-') from each cell line
were plated onto 75 cm' flasks. Forty-eight hours following
plating, cells were exposed to 0.1. 1.0. 5.0 and 1OgM LCV
for 4 h. After 4 h of LCV exposure. cells were washed twice
with 15 ml of phosphate-buffered saline (PBS) and placed in
fresh medium. Starting at time point 0. duplicate sets of
LCV-treated cells were exposed to 5-FU (10gM) for 2 h at
various intervals, as illustrated in Figure 1. At the end of the
2 h 5-FU exposure. the cells were washed twice in 15 ml of
PBS and placed in fresh medium. Twenty-four hours after
5-FU exposure. cells were harvested from the plates by a
10 min incubation in 3 ml of 0.05% trypsin in 0.05 M EDTA.
Cell pellets were collected in 15 ml tubes (Falcon) by centri-
fugation for 10 min at 1000 g. Pellets were resuspended in
QL 1 -
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1 ml of PBS and transferred to 1.2 ml Eppendorf tubes and
pelleted at 1000g. The PBS was aspirated and replaced with
100pl of 0.1 M potassium dihydrogen phosphate buffer.
pH 7.2. Cell lysates were prepared by sonification of cells
using a sonicator. followed bv centrifugation in an Eppen-
dorf refrigerated microfuge at 15000g for 15 min at 4°C.
Proteins were determined by the BioRad method (Bradford.
1976).
WVestern blot anal!sis
Western blot analysis using monoclonal antibody TS 106 was
accomplished as previously described (Johnston et al.. 1991).
Equal amounts of cytosol (300 gg) were resolved by a 15%
polyacrylamide gel electrophoresis according to the method
of Laemmli (1970). Gels were then electrotransferred onto
nitrocellulose membranes (Schleicher & Schull. Keene. NH,
USA). Membranes were treated with blocking solution.
washed and reacted with TS 106 antibody (10Lg ml-'). Blots
were then overlaid with antimouse secondary antibody (10 iLg
ml-') conjugated with horseradish peroxidase (BioRad). Pro-
tein bands representing complex and free TS were detected
colonrmetrically using 3'.5'-tetramethylbenzidine (TMB)
(Figure 2). TS protein detected on the blots was quantitated
by scanning densitometry using an HP Scan Jet digital
imager coupled with NIH Image softare package (v.1.52;
Wayne Rasband. National Institute of Mental Health. Beth-
esda, MD. USA) (Johnston et al.. 1991). The densitometry
signals generated from Western blots were converted to arbi-
trary units by setting the free TS level in 5-FU alone treated
cells at 1. All other comparative values were extrapolated to
this point.
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Figure 1 The 5-FL LCV treatment schedule. An equal number
of cells (I X 106 cells) from each cell line were plated onto
75 cm2 flasks. Forty-eight hours following plating. cells were
exposed to 0.1. 1.0. 5.0 and IO j.M LCV for 4 h. Starting at time
point 0. duplicate sets of LCV-treated cells were treated at
various intervals with 5-FU (10;M) for 2 h as illustrated. All cells
were washed twice with PBS and fresh medium supplied. Cells
were harsested 24 h after 5-FU exposure.
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Fiure 2 Western blot analysis using monoclonal antibodv TS
106 of cell lysates from MCF-7 cells (a) or NCI H630 celis (b)
treated with various combinations of 5-FU LCV and 5-FU and
LCV alone. Western blotting was accomplished as described in
Materials and methods. The band at 36 kDa represents free TS:
the band at 38.5 kDa represents ternary complexed TS.Analysis ofintracellular folate polvglutamates
MCF-7 or NCI H630 cells (1 x lO-ml) were seeded onto
75cm2 flasks. After 48 h, cells were exposed to 1OgM LCV
with 10pCi [3'.5',7,9-3H]6S-leucovorin; Moravek Biochemi-
cals. Brea, CA. USA) for 4 h. After 4 h. cells were washed
with PBS and harvested either immediately or after an addi-
tional 14 h in media without radiolabel. At the end of each
time period, the cells were washed twice with ice-cold PBS
and harvested in 1 ml of 1 x PBS with the aid of rubber cell
scraper. A 100 Lp aliquot was removed for protein quantita-
tion. The folate polyglutamates were extracted from the
remainder of the cell suspension by boiling for 90 s in 2 ml of
2% ascorbate, 2% 2-mercaptoethanol solution, pH 6.0. The
denatured protein was removed by centnrfugation at 1O 000 g
for 5 min. The polyglutamated folates were then concentrated
using a C-18 Sep-Pak cartridge and separated by high-per-
formance liquid chromatography (HPLC) using a 30 min
linear gradient from 20% to 35% acetonitrile in Pic A
(pH 5.5) according to previously published methods (Boar-
man and Allegra. 1992).
Results
Measurement ofthe TS ternary complex to TSfree ratio
MCF-7 breast and NCI H630 colon cancer cells were expos-
ed to LCV concentrations ranging from 0.1 to 1OJtM for 4 h.
and 1O JiM 5-FU for 2 h. either simultaneously with LCV or
at various time points thereafter, as shown schematically in
Figure 1. The effect of the 5-FU LCV schedule upon TS
ternary complex formation was examined for an interval of
24 h from the start of LCV exposure using concentrations of
5-FU LCV that were non-growth inhibitory (5-lO% growth
inhibition). The concentration range of LCV (0.1 -10 IM)
represented the clinically achievable range, and a 2 h
exposure to 5-FU (10JuM) was chosen to be minimally cyto-
toxic, permitting measurement of ternary complex in viable
cells (Figure 2). All measurements of TS ternary complex
were performed 24 h after 5-FU exposure.
In MCF-7 cells. the maximal TS ternary complex forma-
tion occurred when 5-FU was delayed for 4 h after the start
of LCV administration (Figure 3a). This resulted in a 1.8-
± 0.2-fold increase in TS ternary complex to free TS ratio
over that seen when both drugs were added simultaneously
(Figure 3a). A similar effect was apparent in NCI H630 cells;
however, maximal TS ternary complex formation occurred
when 5-FU was delayed for 18 h after the start of the 4 h
LCV exposure (Figure 3b). This resulted in a 1.75- ± 0.23-
fold increase in the ratio of TS ternary complex to free TS
over that seen when both drugs were used simultaneously
(Figure 3b). TS ternary complex formation increased with
increasing LCV dose (0.1-10IM) in both MCF-7 and H630
cells; however, the time peak ternary complex formation (4
and 18 h, respectively) remained constant for each cell line,
independent of the LCV dose used (Figure 3a and b). In both
MCF-7 and H630 cells, the total amount of TS ternary
complex formed was 1.2- to 2.6-fold higher in cells treated
with the combination of 5-FU,LCV than in cells treated with
5-FU alone, depending on the dose and schedule used.
Analysis oftotal TS, TS complex andfree TS
Owing to the differences in the time to maximal ternary
complex formation in these two cell lines, we investigated the
patterns of increase in TS ternary complex, free TS and the
total TS enzyme in both cell lines using 0.1 and 10gIM
concentrations of LCV. In MCF-7 cells exposed to 5-FU
(10JM) LCV (10IM). the total TS increased by up to 2.7-
fold compared with the TS level in MCF-7 cells treated with
LCV (IO M) alone depending on the schedule used (Figure
4a). This compared with a 1.4-fold increase in total TS when
MCF-7 cells were exposed to 5-FU (10 IM) alone. The great-
est increase in total TS was noted when 5-FU was delayed
for 4h after the start of LCV (10JIM) exposure. While TS
Dose and ineval of 54luoouraci and leuwin
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Figure 3 The effect of LCV concentration (0-*. 10gM; *-*.
5pIM: O-O. 1p.: 0-0. 0.1 pM) and exposure interval
between LCV and 5-FU on the TS ternary complex to free ratio
in MCF-7 (a) and NCI H630 cells (b). The TS complex to free
ratio was determined by Western immunoblot analysis using the
TS 106 antibody. TS protein bands representing complex and free
TS were detected colorimetrically using TMB method and quan-
titated by scanning densitometry. Each point presents the
mean ± s.e. of at least six separate expenrments.
ternary complex formation was also maximal after 4 h. the
amount of free TS in MCF-7 cells did not change signifi-
cantly among the various time points of 5-FU delay for up to
24 h (Figure 4a). A similar trend in intracellular TS levels
was found in MCF-7 cells treated with 0.1 I M LCV and
10JM 5-FU. The total TS increased by up to 2.0-fold while
the free TS remained unchanged (data not shown).
In NCI H630 cells exposed to 5-FU (10 ILM) and LCV
(IOJiM), the TS total increased by up to 3.1-fold (Figure 4b).
whereas only a 1.6-fold increase in total TS was observed
when H630 cells were exposed to 5-FU (IO M) alone. In
contrast to MCF-7 cells, the total TS continued to increase
up to an 18 h delay between the start of LCV and 5-FU
exposure. The amount of free TS remained relatively
unchanged in H630 cells whether 5-FU was given concurrent
with LCV or delayed for up to 24 h (Figure 4b). Similar
patterns in TS protein levels were observed using 0.1 JIm
LCV (data not shown).
Folate polvglutamation profile
The pattern of intracellular folate polyglutamation is an
important determinant of intracellular folate retention and
their affinity for TS. It is also an important determinant in
ternary complex formation with TS and FdUMP. We exa-
mined the extent of polyglutamation of LCV to the higher
polyglutamates (Glul-Glu,) at 4 and 18 h after the start ofDose and inkerval o 5fluorouraci and eucomoin
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Table I Folate polyglutamates Glu,
MCF-7
4 h 16.3 2.2
18 h 12.3 1.8
aHigher (Glu -Gluo) folate polyglutamation profil
NCI H630 cells 4 and 18 h after the start of the 4 E
The results are the mean ± s.d. of three separate c
LCV exposure. These represented the time poij
TS protein and TS ternary complex formation
NCI H630 cells respectively. In MCF-7 cel
polyglutamates were maximal after 4 h (1
mg-1) compared with the 18 h time point (I
mg-'). In contrast, the Glu,-Glu, level in N
was 2-fold lower at the 4 h point (3.1 ± 0.6 pn
at the 18 h time (6.5 ± 0.8 pmol mg-') (Tablc
This study has examined the effect of a variei
and concentrations of LCV on TS ternary co
and total TS levels in MCF-7 breast and N(
cancer cells treated with 5-FU. TS ternary c
tion was greater at all LCV exposures studied
cells treated With 5-FU alone; moreover. t]
ternary complex formed increased with increa!
centration. The pattern of increase of TS ter
free TS and total TS was dependent on the tre;
in both cell lines. In MCF-7 cells. complex
maximal when 5-FU was delayed for 4 h after
LCV exposure. wkhereas in H630 cells TS complex was max-
imal after an 18 h 5-FU delay. The point of maximal ternary
complex formation was similar for each LCV dose used in
Total TS both cell lines. This time-dependent variation in maximal TS
complex formation was reflective of the total intracellular TS
level. In MCF-7 cells. total TS levels were maximal at the 4 h
5-FU delay time point, whereas in H630 cells the amount of
Complex TS total intracellular TS continued to increase when cells were
exposed to 5-FU for up to 18 h after LCV exposure. Since an
increase in ternary complex formation paralleled the increase
Free TS in total TS. the amount of intracellular free TS did not
change in either cell line. These patterns in TS levels were
independent of LCV dose. Thus. the level of intracellular free
TS present at longer 5-FU delay time points was similar to
that obtained by giving both drugs simultaneously. This
suggests that the effect of LCV on enhanced ternary complex
formation is present for up to 18 h after removal of the LCV,
presumably because of the prolonged retention of folate
polyglutamates (Table I).
The results also demonstrate that the combination of 5-
+ Total TS FU LCV resulted in a 2- to 3-fold greater increase in total
TS protein over that seen with 5-FU alone; moreover. the
amount of total TS protein increased in proportion to LCV
4 Complex TS dose and depended on the delay in 5-FU exposure. This
time-dependent increase in TS protein would appear to be a
function of the rate of formation of higher folate poly-
glutamates. Induction of TS protein synthesis may be respon-
o Free TS sible for the increased total TS protein and may be an
important cellular response to 5-FU LCV, as has been
previously described in cells treated with 5-FU alone (Chu et
24 al., 1993); however, this does not lead to increased free TS
levels, as the majority of this newly synthesised TS becomes
bound as ternary complex. The effect of LCV in potentiating
)mplex TS free 5-FU is dependent on the degree of folate polyglutamation.
-e (0-0) in Polyglutamation of the folate leads to enhanced affinity for
FU (101M) at TS and increased intracellular retention (Houghton et al..
line represents 1990; Romanimnet al.. 1991; Machover et al.. 1992). In this
ated with leu- study using a 4 h exposure to LCV, we found 5-fold higher
can ± s.e. of at polyglutamate levels in MCF-7 cells compared with NCI
H630 cells 4 h after the LCV exposure; however. the accumu-
lation of folate polyglutamates continued to increase in H630
cells. This difference in polyglutamate profile may account
for the greater effect on TS at earlier time points in the
H630 MCF-7 cells as a result of increased ternary complex forma-
3.1 ± 0.6 tion and stability. Other studies have shown that metabolism
6.5 ± 0.8 to the higher polyglutamate forms is both time and dose
le in MCF-7 and dependent; however, the duration of LCV exposure appears
i LCV exposure. to be the most critical factor for folate polyglutamation
experiments. (Houghton et al.. 1990: Romanini et al., 1991). While many
studies have measured the extent of polyglutamation, the
level of total intracellular reduced folates and 5,10-methyl-
ene-H4PteGlu, they have not examined the amount of ternary
nts of maximal complex formation in relation to varying doses and schedules
in MCF-7 and of LCV. Several studies in patients with breast and colon
lls. the higher tumour biopsies have demonstrated that the amount of ter-
16.3 ± 2.2 pmol nary complex formed appears to predict for tumour respon-
12.3 ± 1.8 pmol siveness (Spears et al., 1982; Swain et al., 1989). Patients with
ICI H630 cells more than 80% of their tumours TS in the form of ternary
nol mg-') than complex tended to have relatively responsive disease. Thus,
I). the percentage of TS complexed may be an important deter-
minant of response to 5-FU LCV. A number of preclinical
studies have shown that LCV potentiates 5-FU cytotoxicity
by increasing the formation and stability of ternary complex
formation. In L1210 cells. Ullman et al. (1978) demonstrated
ty of schedules that doses of LCV above 0.5 gM produced a 5-fold increase
,mplex. free TS in growth inhibition and a 12-fold increase in ternary com-
C1 H630 colon plex formation. Other investigators have also demonstrated
omplex forma- in vitro that concentrations of LCV ranging from 1.0 to
compared with 10gM are required for optimal growth inhibition (Ullman et
he amount of al.. 1978: Keyomarsi and Moran. 1986; Mini et al.. 1987;
sing LCV con- Petrelli et al.. 1987; Park et al., 1988; Moran and Scanlon.
mnary complex. 1991). In these preclinical studies. LCV was only effective in
atment interval enhancing 5-FU activity when given before or simultaneously
formation was with 5-FU (Houghton et al., 1990; Romanii et al.. 1991;
the start of the Machover et al.. 1992). These studies suggested that LCVDose and infval o 5-fluorouracil and kuco,oin
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levels of 1-10 Lm are required to optimise the LCV effect in
clinical studies.
A large number of phase II clinical studies in colorectal
cancer have demonstrated an increased response rate in
patients receiving 5-FU plus LCV compared with 5-FU alone
(Machover et al.. 1986; Erlichman et al., 1988; Petrelli et al..
1989; Poon et al.. 1989; Valone et al.. 1989; Advanced Colo-
rectal Cancer Meta-Analysis Project. 1992). In order to
achieve the target concentrations of LCV defined by preclini-
cal investigations (1-1OI1M) clinical investigators have used
a variety of doses and schedules of LCV. In patients. high-
dose LCV therapy (200-500 mg m-2) can achieve plasma
levels of 10-50 1M, while low-dose regimens (20-50 mg m-2)
result in reduced folate levels in the 1 JIm range (Trave et al..
1989; Gerstner et al., 1991; Priest et al.. 1991; Machover et
al.. 1992). Differences in response to 5-FU, LCV combina-
tions have been noted with regard to LCV dose in some
studies. Patients on a North Central Cancer Tumor Group
study were randomised to receive 370 mg m- with LCV
200mgm-2 day-' for 5 days every 4-5 weeks or 5-FU
425 mg m-2 plus LCV 20 mg m-' daily for 5 days every 4-5
weeks. Those patients who received low-dose LCV had a
better response rate than those who received a high-dose;
however, there was no difference in survival (Poon et al.,
1989). Patients on the low-dose arm received 15% more
5-FU, which may have accounted for some of the increase
seen in response rate. Another study, by Petrelli et al. (1989),
compared 5-FU alone (500 mgm-) with identical doses of
5-FU with either low-dose LCV (25 mg m-) given as a
15mmn infusion or high-dose LCV (500 mgm--) given as a
2 h infusion. The response rate in the high-dose arm was
significantly higher than in the 5-FU-only arm. The response
rate between the low-dose LCV and 5-FU alone was not
statistically different (Petrelli et al.. 1989). Thus. the data
from these studies suggest that low-dose LCV may be as
effective as high-dose LCV when using a repetitive dosing
schedule (daily for 5 days). but not with a weekly schedule.
in which case dose appears to be important. One possible
explanation for this observation is that the effect of low-dose
LCV on ternary complex formation persists for up to 24 h
after LCV exposure. as demonstrated by this study. With
daily doses of LCV. each dose would have an effect on
ternary complex formation. in addition to the persistent
effect of the previous dose. A similar phenomenon may not
occur with a longer weekly interval.
In conclusion, these studies suggest that low-dose LCV
(0.1 M) is as effective in the formation of TS ternary com-
plex within a cell as high-dose LCV (10gm) when used as a
4 h exposure. Increasing the LCV dose 100-fold or delaying
5-FU by up to 24 h after LCV exposure results in increases
in total TS and TS ternary complex but does not change the
amount of free TS in either cell line. Time- and dose-depen-
dent increases in TS ternary complex and TS total protein
appear to be due to differences in the accumulation of folate
polyglutamates between these cell lines. These observations
will be incorporated into future clinical strategies using
leucovorin modulation of 5-FU.
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